MCK - McKesson Corporation
153.96 0.00 (0.00%)
After hours: 5:02PM EDT
| Previous Close | 151.71 |
| Open | 153.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 150.17 - 154.20 |
| 52 Week Range | 134.25 - 178.86 |
| Volume | 1,818,460 |
| Avg. Volume | 1,769,153 |
| Market Cap | 31.768B |
| Beta | 1.49 |
| PE Ratio (TTM) | 6.77 |
| EPS (TTM) | 22.74 |
| Earnings Date | May 16, 2018 - May 21, 2018 |
| Forward Dividend & Yield | 1.36 (0.90%) |
| Ex-Dividend Date | 2018-02-28 |
| 1y Target Est | 178.88 |
- TheStreet.com•4 hours ago
McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids
An internal review of management behavior at the healthcare company over opioid distribution prompted by complaints from shareholder International Brotherhood of Teamsters gives company officials a clean ...
- The Wall Street Journal•15 hours ago
[$$] McKesson Launches Comprehensive Review of Operations
As part of its revamped focus, the drug distributor agreed to buy Medical Specialties Distributors from New Mountain Capital.
- Business Wire•yesterday
McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook and Provides Preliminary Fiscal 2019 Outlook
McKesson Corporation (MCK) today announced a multi-year strategic growth initiative, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance. McKesson expects investments in these areas will accelerate the company’s growth trajectory over the long term.
- Reuters•3 days ago
Glenview's Robbins says talk of Amazon's entering pharma is overblown
Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns, citing CVS Health Corp (CVS.N), McKesson Corp (MCK.N) and Express Scripts Holdings (ESRX.O). Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business, Robbins said. Amazon's entry into the business of selling medications, is "neither imminent, assured, nor likely to succeed," he said.
- Yahoo Finance•3 days ago
Hedge fund billionaire explains why Amazon won't get into pharma
Amazon hasn't obtained pharamcy licenses to sell pills.
- Reuters•3 days ago
Glenview's Robbins says talk of Amazon's entering pharma is overblown
Glenview Capital Management Chief Executive Larry Robbins said on Monday at the Sohn Investment Conference in New York that he still likes a trio of stocks he already owns, citing CVS Health Corp, McKesson Corp and Express Scripts Holdings. Amazon has not made significant hires in the pharmacy business and does not have the licenses needed to enter the business, Robbins said. Amazon's entry into the business of selling medications, is "neither imminent, assured, nor likely to succeed," he said.
- Bloomberg•3 days ago
McKesson's Board Clears Itself of Wrongdoing on Opioid Oversight
A year after McKesson Corp. announced a $150 million settlement with the U.S. government over allegations it failed to properly oversee shipments of painkillers, a board committee cleared directors and ...
- CNBC•10 days ago
Drug distributor and drugstore stocks rally after Amazon shelves plan to sell to hospitals
Shares of Cardinal Health, McKesson, AmerisourceBergen, Walgreens Boots Alliance and CVS Health all rose on the news.
- TheStreet.com•13 days ago
Congress Sets Opioid Hearing Next Month for Drug Distributors
A House committee trying to understand how the opioid crisis came to be and what to do next has set a May 8 hearing for drug distributors to explain their role.
Motley Fool•13 days agoRite Aid (RAD) Q4 2018 Earnings Conference Call Transcript
RAD earnings call for the period ending March 3, 2018.
- Simply Wall St.•14 days ago
Want To Invest In McKesson Corporation (NYSE:MCK)? Here’s How It Performed Lately
Examining McKesson Corporation’s (NYSE:MCK) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...
Associated Press•14 days agoOpioid trials to begin in 2019 as settlement is also pushed
COLUMBUS, Ohio (AP) — A federal judge with an audacious plan to settle hundreds of lawsuits filed by local governments against the drug industry over the destruction wrought by prescription opioid painkillers has altered his course.
- American City Business Journals•15 days ago
Your post-surgery pain could be this San Francisco drugmaker's gain and opioid users may benefit, too
Adynxx's first goal is to have its experimental drug block post-surgical pain, but in doing that it appears to have an effect on how many addictive opioids patients will pop.
- TheStreet.com•17 days ago
McKesson Lawsuit Puts Drug Distributors Back Into Harsh Public Spotlight
McKesson and other drug distributors are having a difficult time steering clear of controversy, with the latest blow a lawsuit alleging McKesson has violated the False Claims Act.
- American City Business Journals•20 days ago
Netsmart buys 200-person business from one of the world's largest health care companies
Netsmart will acquire the home health and hospice businesses from one of the world's largest health care companies.
- American City Business Journals•21 days ago
Exclusive: WeWork's massive growth fuels talks for two major S.F. leases
The co-working company, valued at $20 billion, shows no signs of slowing after a blockbuster year in 2017.
- American City Business Journals•27 days ago
Opioid distributor McKesson pledges $100 million foundation gift to fight addiction epidemic
Opioids were responsible for 115 deaths of Americans per day in 2016. Now the San Francisco-based company responsible for distributing many of those painkillers is proposing ways to fight the opioid crisis.
- Morningstar•28 days ago
Healthcare: Values Among Drug, Biotech, and Supply Chain Firms
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the first- quarter.
- Simply Wall St.•last month
Best Undervalued Stock in March
Stocks, such as McKesson, trading at a market price below their true values are considered to be undervalued. There’s a few ways you can measure the value of a companyRead More...
- Zacks•last month
Is McKesson Corporation (MCK) a Suitable Value Stock Now?
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Markit•last monthSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
Markit•last monthSee what the IHS Markit Score report has to say about McKesson Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Over the last one-month, outflows of investor capital in ETFs holding MCK totaled $2.54 billion.
Markit•last monthSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
- Market Realist•2 months ago
Behind Depomed’s Business Strategy
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
